• Three formulations utilizing solubilization technologies were studied: (1) an amorphous inclusion complex of ziprasidone mesylate and a cyclodextrin, (2) a nanosuspension of crystalline ziprasidone...

    Publication
     
  • This work shows development of a scale up correlation using computational fluid dynamic (CFD) simulations for floating solids drawdown operation in stirred tanks. Discrete phase modeling (DPM)...

    Publication
     
  • The impact of hydrodynamics on agglomeration during the crystallization of an active pharmaceutical ingredient (API) was investigated. The type of agglomerate formed was experimentally observed to...

    Publication
     
  • This webinar will address scientific and practical aspects of formulation selection and process design relative to early- and late-stage pharmaceutical development.

    Webinar
     
  • This study explored the utility of topically applied polymeric nanoparticle suspensions to target delivery of poorly water-soluble drugs to hair follicles. Several formulations of amorphous drug/...

    Publication
     
  • Amorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules and have proved well suited to dosing in suspension and...

    Webinar
     
  • To address the need for formulations with increased oral bioavailability, Bend Research has developed a patented technology platform based on spray-dried dispersions(SDDs)to enhance the delivery of...

    Tech Brief
     
  • At Bend Research, we believe fundamental scientific understanding is the cornerstone of leading-edge technology development. Our commitment to the gathering and application of this understanding...

    Tech Brief
     
  • A broad range of formulation needs can be addressed with oral mutliparticulate technology available at Bend Research. Pellets, beads, and microspheres with coasted and/or matrix architectures can be...

    Tech Brief
     
  • Pharmaceutical firms often desire to delivery crystalline and solubilized forms of compounds in once- or twice-daily dosing regimes to maximize therapeutic effect and patient compliance. To meet this...

    Tech Brief
     
  • An estimated 25-30% of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in economic and therapeutic opportunity. Because many of these...

    Tech Brief
     
  • Ocular drug delivery presents unique challenges and opportunities. Eye tissues can be accessed directly with relative ease using topical eye drops. However, the loading and ocular absorption of drugs...

    Tech Brief
     

Pages